{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:19:27Z","timestamp":1790936367810,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1053\/sonc.2002.30142","type":"journal-article","created":{"date-parts":[[2002,8,24]],"date-time":"2002-08-24T23:46:10Z","timestamp":1030232770000},"page":"70-74","source":"Crossref","is-referenced-by-count":47,"special_numbering":"S2","title":["Emerging information on the use of rituximab in chronic lymphocytic leukemia"],"prefix":"10.1053","volume":"29","author":[{"given":"Michael J","family":"Keating","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Albitar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/sonc.2002.30142_BIB1","first-page":"511","article-title":"CD20 workshop panel report","author":"Zhou","year":"1995"},{"key":"10.1053\/sonc.2002.30142_BIB2","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.30142_BIB3","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","volume":"49","year":"1982","journal-title":"Cancer"},{"key":"10.1053\/sonc.2002.30142_BIB4","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O'Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.30142_BIB5","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.30142_BIB6","first-page":"369a","article-title":"Clinical relevance of circulating CD20 (cCD20) in patients with chronic lymphocytic leukemia (CLL)","volume":"96","author":"Manshouri","year":"2000","journal-title":"Proc Am Soc Hematol"},{"key":"10.1053\/sonc.2002.30142_BIB7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/cbr.1997.12.177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/sonc.2002.30142_BIB8","first-page":"1466","article-title":"Fludarabine synergizes with anti CD20 monoclonal antibody rituximab in complement mediated cell lysis","volume":"96","author":"Golay","year":"2000","journal-title":"Proc Am Soc Hematol"},{"key":"10.1053\/sonc.2002.30142_BIB9","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"key":"10.1053\/sonc.2002.30142_BIB10","first-page":"514a","article-title":"Combination chemo-antibody therapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) achieves a high CR rate in previously untreated chronic lymphocytic leukemia (CLL)","volume":"96","author":"Keating","year":"2000","journal-title":"Proc Am Soc Hematol"},{"key":"10.1053\/sonc.2002.30142_BIB11","first-page":"757a","article-title":"Combination fludarabine, cyclophosphamide, and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL)","volume":"96","author":"Garcia-Manero","year":"2000","journal-title":"Proc Am Soc Hematol"},{"key":"10.1053\/sonc.2002.30142_BIB12","first-page":"280a","article-title":"Rituximab added to fludarabine improves response in previously untreated chronic lymphocytic leukemia: Preliminary results from CALGB 9712","volume":"20","author":"Byrd","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/sonc.2002.30142_BIB13","first-page":"73","article-title":"Mechanism-based rationales for combination therapies of lymphoid malignancies","volume":"84","author":"Plunkett","year":"1999","journal-title":"Haematologica"},{"key":"10.1053\/sonc.2002.30142_BIB14","first-page":"371a","article-title":"Quantitative difference in CD20 expression in chronic B-cell lymphocytic leukemia and lymphomas by site and type of disease","volume":"96","author":"Huh","year":"2000","journal-title":"Proc Am Soc Hematol"},{"key":"10.1053\/sonc.2002.30142_BIB15","first-page":"771a","article-title":"Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia","volume":"98","author":"Wierda","year":"2001","journal-title":"Proc Am Soc Hematol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775402500798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775402500798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T14:57:07Z","timestamp":1581001027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775402500798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["S0093775402500798"],"URL":"https:\/\/doi.org\/10.1053\/sonc.2002.30142","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}